BioSpace News Archive

Nexus Health Capital’s Corporate Social Responsibility Program, recently announced by William Lautman, expands its scope to sponsor Golf Fore Africa to build a water-well in Zambia.

PTS Diagnostics, a U.S.–based manufacturer of point-of-care biometric testing devices, today announced that they are expanding operations in Indianapolis and building a new global headquarters.

The federal agency’s pushback on criticism of its flawed framework for determining the health risk of asbestos underestimates the deadly carcinogen.

The U.S. Food and Drug Administration today approved Annovera (segesterone acetate and ethinyl estradiol vaginal system), which is a combined hormonal contraceptive for women of reproductive age used to prevent pregnancy and is the first vaginal ring contraceptive that can be used for an entire year.

The Consumer Healthcare Products Association (CHPA) applauds Colorado for enacting a law prohibiting the sale of over-the-counter (OTC) medicines containing the cough suppressant dextromethorphan (DXM) to minors this week.

First and Only FDA-approved Treatment Available in the United States for this Indication

The first and only birth control approved as a vaginal system

State Recognizes Methodist Charlton can care for patients suffering from major traumatic injuries

ProtoKinetix Inc., Incorporated has entered into the 3rd phase of testing in retinal cell replacement therapy at the University of British Columbia.

The U.S. Food and Drug Administration today approved Galafold (migalastat), the first oral medication for the treatment of adults with Fabry disease. The drug is indicated for adults with Fabry disease who have a genetic mutation determined to be responsive (“amenable”) to treatment with Galafold based on laboratory data.